Literature DB >> 15943393

Market-oriented health care reforms and policy learning in the Netherlands.

Jan-Kees Helderman1, Frederik T Schut, Tom E D van der Grinten, Wynand P M M van de Ven.   

Abstract

In this article we analyze the evolution of market-oriented health care reforms in the Netherlands. We argue that these reforms can be characterized as policy learning within and between competing policy programs. Policy learning denotes the process by which policy makers and stakeholders deliberately adjust the goals, rules, and techniques of a given policy in response to past experiences and new information. We discern three distinctive periods. During the first period (1988-1994), the prevailing corporatist and etatist policy programs were seriously challenged by the proponents of a new market-oriented program. But when it came to political decision making and implementation, the market-oriented program soon lost its impetus because it was technically too complex and could not provide short-term solutions to meet the urgent need for cost containment. During the second period (1994-2000), the etatist program regained its previously dominant position. In parallel to a strengthening of supply and price controls, however, the government also persevered in creating the technical and institutional preconditions for regulated competition. Moreover, public discontent over waiting lists and the call for more autonomy by individual providers and insurers strengthened the alliance in favor of regulated competition. This led to the revival of the market-oriented program in a 2001 reform plan. We conclude that the odds of these new post-2001 reforms succeeding are substantially higher than in the first period due to the technical and institutional adjustments that have taken place in the past decade.

Mesh:

Year:  2005        PMID: 15943393     DOI: 10.1215/03616878-30-1-2-189

Source DB:  PubMed          Journal:  J Health Polit Policy Law        ISSN: 0361-6878            Impact factor:   2.265


  10 in total

1.  A public-private analysis of the new Dutch health insurance system.

Authors:  Hans Maarse; Yvette Bartholomée
Journal:  Eur J Health Econ       Date:  2007-03

2.  Political challenges for healthcare reform.

Authors:  Lawrence D Brown
Journal:  Pharmacoeconomics       Date:  2006-12       Impact factor: 4.981

3.  Including citizens in institutional reviews: expectations and experiences from the Dutch Healthcare Inspectorate.

Authors:  Samantha A Adams; Hester van de Bovenkamp; Paul Robben
Journal:  Health Expect       Date:  2013-09-24       Impact factor: 3.377

4.  Data sets on pensions and health: Data collection and sharing for policy design.

Authors:  Jinkook Lee
Journal:  Int Soc Secur Rev       Date:  2010-07

5.  Health sector solidarity: a core European value but with broadly varying content.

Authors:  Richard B Saltman
Journal:  Isr J Health Policy Res       Date:  2015-04-17

6.  How nurses and their work environment affect patient experiences of the quality of care: a qualitative study.

Authors:  Renate Amm Kieft; Brigitte B J M de Brouwer; Anneke L Francke; Diana M J Delnoij
Journal:  BMC Health Serv Res       Date:  2014-06-13       Impact factor: 2.655

7.  Politics of policy learning: Evaluating an experiment on free pricing arrangements in Dutch dental care.

Authors:  Martijn Felder; Hester van de Bovenkamp; Antoinette de Bont
Journal:  Evaluation (Lond)       Date:  2018-01-19

8.  Quantitative data management in quality improvement collaboratives.

Authors:  Mireille van den Berg; Rianne Frenken; Roland Bal
Journal:  BMC Health Serv Res       Date:  2009-09-26       Impact factor: 2.655

9.  Making Markets in Long-Term Care: Or How a Market Can Work by Being Invisible.

Authors:  Kor Grit; Teun Zuiderent-Jerak
Journal:  Health Care Anal       Date:  2017-09

Review 10.  Steering by their own lights: Why regulators across Europe use different indicators to measure healthcare quality.

Authors:  Anne-Laure Beaussier; David Demeritt; Alex Griffiths; Henry Rothstein
Journal:  Health Policy       Date:  2020-02-29       Impact factor: 2.980

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.